CEFTRIAXONE ZENTIVA 500 mg/2 ml, powder and solvent for solution for injection (IM) bottle, 2 ml
Active ingredients: Ceftriaxone, Ceftriaxone sodium heptahydrate
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for solution for injectionbottle, 2 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CEFTRIAXONE ZENTIVA 500 mg/2 ml, poudre et solvant pour solution injectable (IM)
- Pharmaceutical form
- poudre et solvant pour solution injectable
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre de 500 mg - 1 ampoule(s) en verre de 2 ml
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 May 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62791557CIP73674420CIP133400936744202Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CEFTRIAXONE SODIQUEpoudre | 539,635 mg · un flacon de poudre | SA |
| CEFTRIAXONE BASEpoudre | 500 mg · un flacon de poudre | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.